CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Daewoong Pharma is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Daewoong Pharma
35-14, Jeyakgongdan 4-gil, Hyangnam-eup
Phone: +82 25508800p:+82 25508800 HWASEONG, 18623  South Korea Ticker: 069620069620
Business Summary
Daewoong Pharma is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The Company distributes its products in domestic and overseas markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-President, Co-Chief Executive Officer, Director Seung HoJeon 46 3/23/2018 3/23/2018
Co-President, Co-Chief Executive Officer, Director Chang JaeLee 45 1/3/2022 1/3/2022
Co-President, Co-Chief Executive Officer, Director Jae ChunYoon 62 3/23/2018 3/23/2018
4 additional Officers and Directors records available in full report.

Business Names
Business Name
069620
Daewoong Pharmaceutical Co., Ltd.

General Information
Number of Employees: 1,256 (As of 12/31/2010)
Outstanding Shares: 11,506,270 (As of 9/30/2024)
Shareholders: 29,217
Stock Exchange: KRX
Fax Number: +82 220591690


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024